Group 1 - The company stated that its catalyst products can be used in the development of innovative drugs, pharmaceutical intermediates, and active pharmaceutical ingredients [2] - By the first half of 2025, the revenue from the pharmaceutical sector is expected to account for 40.51% of the company's total catalyst income [2]